An 8-week study to evaluate the efficacy (blood pressure lowering effect) and safety of LCZ696 given alone and in combination with amlodipine

Registry ID

EUCTR2013-001643-30

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2013-10-09

Last update

2026-08-16

Conditions

• Essential hypertension

Summary

To evaluate the blood pressure lowering effect and safety of LCZ696 when given alone and in combination with amlodipine in patients with essential hypertension.

Locations

• , , Slovakia
• , , Spain

View on source registry